Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
McKinsey
Citi
AstraZeneca
Argus Health
Boehringer Ingelheim
Cantor Fitzgerald
Cipla
Mallinckrodt
Baxter

Generated: January 21, 2018

DrugPatentWatch Database Preview

Claims for Patent: 4,567,264

« Back to Dashboard

Summary for Patent: 4,567,264
Title: Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
Abstract:Novel compounds of the general formula ##STR1## and the pharmaceutically acceptable esters and acid addition salts thereof, wherein: R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each independently hydrogen, lower alkyl, lower alkoxy, cyano, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl, N-optionally substituted alkylamido, except that when R.sup.1 is methyl, R.sup.4 is not methyl; or R.sup.2 and R.sup.3 together form --OCH.sub.2 O--; R.sup.6, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are each independently hydrogen, lower acyl, aminocarbonylmethyl, cyano, lower alkyl, lower alkoxy, trifluoromethyl, halo, lower alkylthio, lower alkyl sulfinyl, lower alkyl sulfonyl, di-lower alkyl amino; or R.sup.6 and R.sup.7 together form --CH.dbd.CH--CH.dbd.CH--; R.sup.7 and R.sup.8 together form --OCH.sub.2 O--; R.sup.11 and R.sup.12 are each independently hydrogen or lower alkyl; and W is oxygen or sulfur. These cardioselective compounds have calcium entry blockade properties and therefore are useful in therapy in the treatment of cardiovascular diseases, including arrhythmias, variant and exercise induced angina and myocardial infarction.
Inventor(s): Kluge; Arthur F. (Los Altos, CA), Clark; Robin D. (Palo Alto, CA), Strosberg; Arthur M. (Menlo Park, CA), Pascal; Jean-Claude G. (Cachan, FR), Whiting; Roger (Edinburgh, GB6)
Assignee: Syntex (U.S.A.) Inc. (Palo Alto, CA)
Application Number:06/495,904
Patent Claims: 1. A compund of the formula: ##STR14## and the pharameutically acceptable esters and acid addition salts thereof, wherein:

R1 and R5 are each methyl

R.sup.2 and R.sup.3 and R.sup.4 are each hydrogen and R.sup.6 to R.sup.12 are each hydrogen, i.e., 1-[3-phenoxy-2-hydroxypropyl]-4-[2,6-dimethylphenyl)-aminocarbonylmethyl]- piperazine, and the pharaceutically acceptable esters and acid addition salts thereof.

2. A compound of the formula: ##STR15## and the pharmaceutically acceptable esters and acid addition salts thereof, wherein:

R.sup.1 and R.sup.5 are each methyl

R.sup.2, R.sup.3, and R.sup.4 are each hydrogen, R.sup.6 is methoxy and R.sup.7 to R.sup.12 are each hydrogen, i.e., 1-[3-(2-methoxyphenoxy)-2-hydroxypropyl]-4-[(2,6,-dimethylphenyl)-aminocar bonylmethyl]-piperazine, and the pharaceutically acceptable esters and acid addition salts thereof.

3. A compound of the formula: ##STR16## and the pharmaceutically acceptable esters and acid addition salts thereof, wherein:

R.sup.1 and R.sup.5 are each methyl;

R.sup.2, R.sup.3, and R.sup.4 are each hydrogen, R.sup.6 is cyano and R.sup.7 to R.sup.12 are each hydrogen, i.e., 1-[3-(2-cyanohenoxy)-2-hydroxypropyl]-4-[2,6-dimethylphenyl)aminocarbonylm ethyl]piperazine.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Federal Trade Commission
US Department of Justice
Fuji
Novartis
Deloitte
Chinese Patent Office
Colorcon
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot